Immutep Granted United States Patent for IMP761, a First-in-Class Agonist Antibody Targeting LAG-3
20 Junho 2023 - 9:00AM
Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage
biotechnology company developing novel LAG-3 immunotherapies for
cancer and autoimmune disease, today announced the grant of a new
patent (number 11,680,104) by the United States Patent Office. The
granted claims are composition-of-matter type claims covering
Immutep’s pre-clinical immunosuppressive product candidate IMP761,
a first-in-class agonist LAG-3 antibody designed to target the root
cause of autoimmune diseases by directly silencing
self-antigen-specific effector T cells.
The patent is owned by Immutep S.A.S. and will
expire on 22 February 2037 (including 174 days of patent term
adjustment). This new United States patent follows the grant of the
equivalent Japanese and European patents announced in July 2022 and
October 2020, respectively. A divisional application has also been
filed to pursue claims drawn to methods of treating T-cell mediated
immune disorders, such as inflammatory or autoimmune diseases, by
administration of IMP761.
Immutep CSO, Dr. Frédéric Triebel, said: “We
have been making good progress in advancing IMP761 towards
potential first-in-human clinical testing. In particular, we
developed a 200L GMP-compliant manufacturing process in
collaboration with our colleagues at Northway Biotech late last
year, and more recently selected Charles River Laboratories to
conduct a GLP toxicology study, a key step prior to first-in-human
trials. In tandem, we continue to build our patent estate around
this first-in-class drug candidate in key markets globally.”
About IMP761IMP761, a
first-in-class immunosuppressive LAG-3 agonist antibody, has the
potential to address the root cause of many autoimmune diseases by
specifically silencing autoimmune memory T cells that accumulate at
disease sites. These T cells express LAG-3 as an “exhaustion
marker” after being repeatedly stimulated with dominant
self-peptides. As published in the Journal of
Immunology in January 2020, encouraging pre-clinical results
were achieved with IMP761 leading to significant inhibition of
inflammatory T cell infiltration. Additional pre-clinical findings
published in Pediatric Research in May 2021 show IMP761 led to
large decreases in effector T cell cytokine secretion in a juvenile
arthritis model.
About ImmutepImmutep is a
clinical-stage biotechnology company developing novel LAG-3
immunotherapy for cancer and autoimmune disease. We are pioneers in
the understanding and advancement of therapeutics related to
Lymphocyte Activation Gene-3 (LAG-3), and our diversified product
portfolio harnesses its unique ability to stimulate or suppress the
immune response. Immutep is dedicated to leveraging its expertise
to bring innovative treatment options to market for patients in
need and to maximise value for shareholders. For more information,
please visit www.immutep.com.
Australian
Investors/Media:Catherine Strong, Citadel-MAGNUS+61 (0)406
759 268; cstrong@citadelmagnus.com
U.S.
Investors/Media:Chris Basta, VP,
Investor Relations and Corporate Communications+1 (631) 318 4000;
chris.basta@immutep.com
Immutep (NASDAQ:IMMP)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Immutep (NASDAQ:IMMP)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024